Opportunities for PET to deliver clinical benefit in cancer: Breast cancer as a paradigm

Cancer Imaging

Volumn 10, Issue 1, 2010, Pages 144-152

  Fleming, Ian N ^a   Gilbert, Fiona J ^a   Miles, Ken A ^b   Cameron, David ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Assessing therapy response; Breast cancer; Diagnosis; Identification of recurrence; Pharmacological biomarker; Positron emission tomography; Predictive biomarker; Staging; Surrogate response biomarker; Tumour subtyping

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; AMG 479; BEVACIZUMAB; BOSUTINIB; CP 751871; DASATINIB; DIACETYL BIS CU 64; EVEROLIMUS; FLUORINE 18; FLUORODEOXYGLUCOSE F 14; FLUORODEOXYGLUCOSE F 18; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; IMC A12; IMC A12 MONOCLONAL ANTIBODY; LAPATINIB; METHYLTHIOSEMICARBAZONE N 4; MK 0646; MONOCLONAL ANTIBODY; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OLAPARIB; PERTUZUMAB; TEMSIROLIMUS; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; HUMAN; PATIENT CARE; PREDICTION; TREATMENT RESPONSE; BREAST TUMOR; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MINIMAL RESIDUAL DISEASE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957917727     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.0020     Document Type: Article

References (54)

1. Turner NC, Jones AL. Management of breast cancer - part I. BMJ 2008; 337: a421. doi:10.1136/bmj.a421. PMid:18614462.
2. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW. Impact of time-of-flight on PET tumor detection. J Nuclear Med 2009; 50: 1315-23. doi:10.2967/jnumed.109.063016. PMid:19617317.
3. Bowen SL, Wu Y, Chaudhari AJ, et al. Initial characterization of a dedicated breast PET/CT scanner during human imaging. J Nuclear Med 2009; 50: 1401-8. doi:10.2967/jnumed.109.064428. PMid:19690029.
4. Mullan PB, Millikan RC. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci 2007; 64: 3219-32. doi:10.1007/s00018-007-7389-z. PMid:17957336.
5. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24: 5366-72. doi:10.1200/JCO.2006.05.7406. PMid:17088570.
6. Schwarz JD, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nuclear Med 2005; 46: 1144-50. (Pubitemid 43741076)
7. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/ HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008; 112: 995-1000. doi:10.1002/cncr.23226. PMid:18098228.
8. 18F-2-Fluoro- 2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004; 22: 1253-59. doi:10.1200/JCO.2004.07.058. PMid:15051773.
9. Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010; 14: 1-182.
10. Aukema TS, Rutgers EJT, Vogel WV, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 2010; 36: 387-92.
11. Groheux D, Hindié E, Rubello D, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nuclear Med Mol Imaging 2009; 36: 1539-42. doi:10.1007/s00259-009-1159-0. PMid:19449002.
12. Lavayssie're R, Cabée A, Filmont J. Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol 2009; 69: 50-8.
13. Murray AD, Staff RT, Redpath TW, et al. Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes. Br J Radiol 2002; 75: 220-8.
14. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG pet: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9.
15. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
16. Brenton JD, Carey LA, Ahmed A, Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005; 23: 7350-7360. doi:10.1200/JCO.2005.03.3845. PMid:16145060.
17. Bertucci F, Finetti P, Cervera N, et al. How different are luminal A and basal breast cancers? Int J Cancer 2009; 124: 1338-48. doi:10.1002/ijc.24055. PMid:19058218.
18. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008; 44: 2781-90. doi:10.1016/j.ejca.2008.09.026. PMid:19013786.
19. Ocaña A, Pandiella A. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 2008; 14: 961-70. (Pubitemid 351302540)
20. Abd El-Rehim DM, Ball G, Finder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-50. doi:10.1002/ijc.21004. PMid:15818618.
21. Kucab JE, Dunn SE. Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 2003; 17: 41-7.
22. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J Mammary Gland Biol Neoplasia 2008; 13: 471-83. doi:10.1007/s10911-008-9104-6. PMid:19023648.
23. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008; 19: 1379-86. doi:10.1093/annonc/mdn291. PMid:18487549.
24. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226-38. doi:10.1158/0008-5472.CAN-06- 3633. PMid:17332353.
25. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-17.
26. Farmer H, McCabe H, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21. doi:10.1038/nature03445. PMid:15829967.
27. Turner NC, Jones AL. Management of breast cancer - part II. BMJ 2008; 337: 164-9.
28. 18F-fluoromisonidazole. Semin Nuclear Med 2007; 37: 451-61. doi:10.1053/j.semnuclmed.2007.07.001. PMid: 17920352.
29. Tan EY, Yan M, Campo L, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009; 100: 405-11. doi:10.1038/sj.bjc.6604844. PMid:19165203.
30. 18F]]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245-52. doi:10.1158/1078-0432.CCR-0688-3. PMid:15073099.
31. 18F]fluoropaclitaxel. Nuclear Med Biol 2007; 34: 823-31. doi:10.1016/j.nucmedbio.2007.04.011. PMid:17921033.
32. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nuclear Med 2008; 49: 255-9. doi:10.2967/jnumed.107. 045526. PMid:18199623.
33. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-803. (Pubitemid 32538187)
34. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009; 113: 509-17. doi:10.1007/s10549-008-9953-0. PMid:18327670.
35. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nuclear Med 2003; 44: 1806-14.
36. Groves AM, Wishart GC, Shastry M, et al. Metabolic-flow relationships in primary breast cancer: Feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nuclear Med Mol Imaging 2009; 36: 416-21. doi:10.1007/s00259-008-0948-1. PMid:18818917.
37. 11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis. Nuclear Med Biol 2005; 32: 437-43. doi:10.1016/j. nucmedbio.2005.03.001. PMid:15982573.
38. Murphy PS, Bergstr€om M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr Pharm Design 2009; 15: 957-65. doi:10.2174/138161209787581977. PMid:19275660.
39. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997; 57: 3415-23.
40. Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leukemia Lymphoma 2009; 50: 1748-9.
41. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 2007; 7: 10-18. doi:10.1102/1470-7330. 2007.0004. PMid:17766210.
42. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.
43. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-88.
44. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993; 11: 2101-11.
45. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8: 36-42. doi:10.1007/s11307-005-0029-9. PMid:16362149.
46. 18F]fluorothymidine positron emission tomography. Eur J Nuclear Med Mol Imaging 2007; 34: 1339-47. doi:10.1007/s00259-007-0379-4. PMid:17333178.
47. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005; 11: 7967-85. doi:10.1158/1078-0432.CCR-05-1302. PMid:16299226.
48. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-7. doi:10.1016/S0960-9776(03) 00106-1.
49. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007; 102: 75-84. doi:10.1007/s10549-006-9316-7. PMid:16897427.
50. 18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008; 14: 7423-9. doi:10.1158/1078-0432.CCR-08-0312. PMid:19010859.
51. BlueCross BlueShield Association (BCBSA). Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer. Chicago, IL: BCBSA; 2004; vol 18, p. 8.
52. Goerres GW, Michel SCA, Fehr MK, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13: 1635-44. doi:10.1007/s00330-002-1720-8. PMid:12835979.
53. Grahek D, Montravers F, Kerrou K, Aide N, Lotz J, Talbot J. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nuclear Med Mol Imaging 2004; 31: 179-88. doi:10.1007/ s00259-003-1348-1. PMid:15129699. (Pubitemid 38173692)
54. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010; 136: 1007-22. doi:10.1007/s00432-009-0746-6. PMid:20091186.